Clinical Trials

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT06764875 2026-03-09

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

840 enrolled

HER2-positive Gastric Cancer

NCT03322267 2026-03-06

Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence

Phase 2 Completed

26 enrolled 6 charts

GastrointestinalGynecologic

Esophageal Squamous Cell Carcinoma

NCT04847063 2026-03-06

Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies

Phase 1 Recruiting

60 enrolled

Appendiceal Neoplasms, Gastrointestinal Neoplasms, Necrosis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

Phase 1/2 Not yet recruiting

626 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT07452601 2026-03-05

Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

90 enrolled

Esophageal Squamous Cell Carcinoma

NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

757 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT06657144 2026-03-02

A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Phase 1 Recruiting

154 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05152147 2026-02-27

HERIZON-GEA-01

920 enrolled

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT07039162 2026-02-27

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT05753306 2026-02-25

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

GastrointestinalOther neoplasm

40 enrolled

Gastric Adenocarcinoma

NCT06447662 2026-02-25

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Phase 1 Recruiting

330 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06282575 2026-02-24

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

286 enrolled

Phase 2 Active not recruiting

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

39 enrolled 8 charts

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04379596 2026-02-23

DG-03

450 enrolled

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05771480 2026-02-23

TOURMALINE

142 enrolled

Biliary Tract Neoplasms

NCT05775159 2026-02-18

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

294 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT06467357 2026-02-17

DESTINY-BTC01

620 enrolled

Biliary Tract Neoplasms

NCT07403435 2026-02-11

Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC

22 enrolled

Esophageal Squamous Cell Carcinoma

NCT07397338 2026-02-09

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

370 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07398339 2026-02-09

DVDMS

30 enrolled

Biliary Tract Neoplasms

NCT07392541 2026-02-06

Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer

29 enrolled

Phase 1 Not yet recruiting

Advanced Biliary Tract Carcinoma

NCT07107750 2026-02-04

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

48 enrolled

Biliary Tract Neoplasms

NCT04550260 2026-01-29

KUNLUN

640 enrolled

Esophageal Squamous Cell Carcinoma

NCT07229625 2026-01-28

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

604 enrolled

Advanced Biliary Tract Cancer

NCT07369791 2026-01-28

NOBLE

76 enrolled

Advanced Biliary Tract Cancer(BTC)

NCT06048133 2026-01-23

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

33 enrolled

Bile Duct Neoplasms, Cholangiocarcinoma

NCT06428409 2026-01-22

MK-9999-02A

220 enrolled

Biliary Tract Neoplasms, Colorectal Neoplasms

NCT06591520 2026-01-21

AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

682 enrolled

Biliary Tract Neoplasms

NCT06548412 2026-01-20

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

50 enrolled

Biliary Tract Neoplasms

NCT06855225 2026-01-14

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

29 enrolled

Phase 1 Active not recruiting

Liver Neoplasms

NCT06076837 2026-01-12

The Seven Trial: Exploiting the Unfolded Protein Response

6 enrolled

Phase 2/3 Not yet recruiting

Pancreatic Cancer Metastatic

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

490 enrolled

HER2-positive Gastric Cancer

NCT07036380 2026-01-09

TACTIC

75 enrolled

Phase 2/3 Active not recruiting

Advanced Biliary Tract Carcinoma

NCT06115499 2026-01-07

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

10 enrolled

Pancreatic Neoplasms

NCT06676449 2026-01-07

TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC

432 enrolled

Esophageal Neoplasms

NCT04203160 2025-12-31

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

Phase 1/2 Terminated

75 enrolled 17 charts

Phase 2 Enrolling by invitation

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07139951 2025-12-31

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for the Treatment of Patients With Gastric and Gastroesophageal Junction Adenocarcinoma at High Risk of Peritoneal Recurrence

16 enrolled

Phase 2 Enrolling by invitation

Clinical Stage I Gastric Cancer AJCC v8

NCT07312578 2025-12-31

Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma

48 enrolled

Phase 2 Active not recruiting

Esophageal Squamous Cell Carcinoma

NCT05945823 2025-12-29

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

53 enrolled